Sign in
Taking people in FrancePhase 2

Tests dostarlimab as first treatment for certain mismatch-repair-deficient cancers

Tests dostarlimab against standard care in adults with advanced non-colorectal cancers.

Key facts

Who runs it
Unicancer
Where
Angers, Avignon Cedex 9, Besancon Cedex, Bordeaux, Brest, Caen Cedex 5, Clermont-Ferrand, Creteil, Dijon, Lille Cedex, Lyon, Marseille, Montivilliers, Nantes, Paris, Paris Cedex 12, Pessac, Poitiers, Reims, Reims Cedex, Rennes Cedex, Rouen Cedex, St Herblain, Strasbourg, Strasbourg Cedex 2, Suresnes, Toulouse Cedex 9, Vandouvre Les Nancy, and Villejuif, FranceSee the 30 sites
Registry title
Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI
Status
Recruiting
Phase
Phase 2
People taking part
120 people, planned
Started
18 Jul 2024
Expected to end
23 Jan 2031
Type of study
Interventional
Record updated
27 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic cancer that has a mismatch repair problem (dMMR/MSI-H) and is not colorectal or endometrial cancer. They must not have had any cancer drug treatment for this stage yet.

Age
18 years or older
Sex
All sexes
Disease stage
Locally advanced or metastatic dMMR/MSI-H solid tumor that cannot be fully removed by surgery, with at least one measurable lesion. The tumor must be one of: small bowel or duodenum adenocarcinoma, gastric or oeso-gastric junction adenocarcinoma with CPS<5, pancreatic adenocarcinoma, biliary tract carcinoma, adrenocortical carcinoma, carcinoma of unknown primary site, grade 3 neuroendocrine carcinoma, or soft tissue sarcoma (not GIST).
Earlier treatment
No earlier systemic cancer treatment for advanced or metastatic disease. Any adjuvant therapy must have ended more than 6 months before the diagnosis of metastatic or recurrent disease. No earlier anti-PD-1, PD-L1 or anti-CTL-4 antibodies or other immunotherapy.
Biomarker or test result
The tumor must be dMMR/MSI-H, and a central review must confirm this before joining.

Main reasons for not taking part

  • Colorectal or endometrial cancer, or any tumor type not on the list
  • Known HIV infection
  • Active autoimmune disease needing systemic treatment in the past 2 years
  • Uncontrolled brain metastases or carcinomatous meningitis
  • Prior bone marrow or solid organ transplant

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Patient must have signed a written informed consent form prior any trial specific procedures
  • 18 years or older patients
  • Documented locally advanced or metastatic disease with no previous systemic anticancer treatment in these settings and not suitable for complete surgical resection
  • Histologically proven, dMMR/MSI-H solid tumors that are not colorectal or endometrial cancers and including one of the following: duodenum and small bowel adenocarcinoma, gastric and oeso-gastric junction adenocarcinoma with CPS<5, pancreatic adenocarcinoma, biliary tract carcinoma including ampulla of Vater adenocarcinoma, adrenocortical carcinoma, carcinoma of unknown primary site, neuroendocrine carcinoma (Grade 3) all primary, and soft tissue sarcoma except Gastro-Intestinal stromal tumor (GIST)
  • If patient received adjuvant therapy for non-metastatic disease, this therapy should be completed more than 6 months before the diagnosis of metastatic or recurrent disease
  • Patients with dMMR/MSI tumor analyzed by IHC, PCR (for Gastric and OGJ adenocarcinoma, and duodenum and small bowel adenocarcinoma only), and/or NGS at the recruiting center should be confirmed by central review within 24h (every anonymized patient analysis reporting will be provided for central review). Patients should not be included in the study until the dMMR/MSI status is confirmed by the review committee
  • Presence of at least one measurable lesion within 28 days before the start of treatment according to RECIST v1.1
  • Eastern Cooperative Oncology Group Performance status (ECOG PS) 0-1
  • Haematological status: absolute neutrophil count (ANC) ≥1.5 x 109/L; platelets ≥100 x 109/L; haemoglobin ≥9 g/dL
  • Adequate renal function: serum creatinine level <120 μM, or clearance >50 ml/min (Modification of the Diet in Renal Disease [MDRD] or Cockcroft and Gault)
  • Adequate liver function: serum bilirubin ≤1.5 x upper normal limit (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 x ULN, unless liver metastases are present, in which case they must be ≤ 5× ULN
  • For patients not taking warfarin: INR <1.5 or PT <1.5 x ULN and either PTT or aPTT <1.5 x ULN. Participants taking warfarin may be included on a stable dose with a therapeutic INR <3.5
  • Women of childbearing potential must have a negative serum pregnancy test performed within 72 hours before the date of randomization
  • Men, and women of childbearing potential (WOCBP) must agree to use adequate contraception for the duration of trial participation and for 4 months after the last dose of dostarlimab (used in first line or at crossover) or for at least 6 months after the last administration of the chemotherapy agent(s) used in the control arm if no crossover with dostarlimab (according to the current version of the SmPC of each chemotherapy agent). Men must also agree to not donate sperm and women must agree to not donate oocytes during the specified period
  • Registration in a National Health Care System
  • Patient is willing and able to comply with scheduled visits, treatment schedule, laboratory tests, tumor biopsies, and other requirements of the study

Who cannot take part

  • Has received treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor agents) within 2 weeks prior to the first dose of adjuvant treatment or is required to receive systemic immunosuppressive medications during the study. Inhaled or topical steroids and adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
  • Received live vaccine within 14 days
  • Known active hepatitis, including the following: Participant has an acute hepatitis and untreated chronic hepatitis B at the pre-inclusion visit. i. Chronic HBV carriers (HBsAg positive, HBcAb positive) can be included provided that they receive effective antiviral therapy (i.e., with nucleos(t)ide analogs) for at least 14 days prior to first dose and are willing to continue for at least 6 months after treatment discontinuation or longer at the discretion of the treating hepatologist. HBV DNA must be adequately suppressed, per institutional or local guidelines, prior to initiation of study intervention. ii. Participants with past HBV infection (HBcAb positive, HBsAg negative) can be enrolled if HBV DNA is undetectable at screening
  • Known prior severe hypersensitivity to investigational product or any component in its formulation
  • Participation in another clinical trial within 30 days prior to the first study treatment administration or concomitantly with the trial
  • Previous exposure to anti-PD-1 or PD-L1 or anti-CTL-4 antibodies or treatment with immunotherapy
  • Previous exposure to any investigational drug within 4 weeks (6 weeks for monoclonal antibodies) before the first dose in the study
  • Previous exposure to any systemic anti-cancer therapy or radiation therapy for the cancer for which the patient is being enrolled
  • Uncontrolled central nervous system metastases or carcinomatous meningitis or other concurrent illness or ongoing or active infections
  • Prior allogeneic bone marrow transplantation or prior solid organ transplantation,
  • Colorectal and endometrial cancer and all primary tumor not listed in inclusion criterion #4
  • Known Human Immunodeficiency Virus (HIV) infection
  • Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Active autoimmune disease: Active autoimmune disease requiring systemic treatment in the past 2 years (excluding replacement therapy) or any history of interstitial lung disease (patients with ancient auto-immune disease with stable endocrine oral substitution are eligible)
  • Other serious and uncontrolled non-malignant disease or is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study,
  • Other concomitant or previous malignancy other than the disease under study, except : i. adequately treated in-situ carcinoma of the uterine cervix, ii. basal or squamous cell carcinoma of the skin, iii. cancer from which the patients was in complete remission for >2 years
  • Pregnant or breast feeding women
  • Person deprived of their liberty or under protective custody or guardianship
  • Patients with HER2-positive gastric carcinoma

This trial is currently available in France.

  • Institut de Cancerologie de L'OuestAngers, FranceTaking people
  • Sainte Catherine Institut Du Cancer Avignon-ProvenceAvignon Cedex 9, FranceTaking people
  • Besancon University Hospital CenterBesancon Cedex, FranceTaking people
  • Institut BergonieBordeaux, FranceTaking people
  • Centre Hospitalier Régional et Universitaire de BrestBrest, FranceTaking people
  • Centre Francois BaclesseCaen Cedex 5, FranceTaking people
  • Centre Jean PerrinClermont-Ferrand, FranceTaking people
  • Assistance Publique Hopitaux De ParisCreteil, FranceTaking people
  • Centr Georges Francois LeclercDijon, FranceTaking people
  • Centre Hospitalier Universitaire De LilleLille Cedex, FranceTaking people
  • Centre Leon BerardLyon, FranceTaking people
  • Assistance Publique Hôpitaux de MarseilleMarseille, FranceTaking people
  • Groupe Hospitalier Du HavreMontivilliers, FranceTaking people
  • Centre Hospitalier Universitaire de NantesNantes, FranceTaking people
  • Assistance Publique Hopitaux de ParisParis, FranceTaking people
  • Institut Medico-chirurgical MontsourisParis, FranceTaking people
  • Hopital Saint AntoineParis Cedex 12, FranceTaking people
  • Centre Hospitalier Universitaire de BordeauxPessac, FranceTaking people
  • Centre Hospitalier Universitaire de PoitiersPoitiers, FranceTaking people
  • Institut GodinotReims, FranceTaking people
  • Centre Hospitalier Universitaire ReimsReims Cedex, FranceTaking people
  • Centre De Lutte Contre Le Cancer Eugene MarquisRennes Cedex, FranceTaking people
  • CHU De RouenRouen Cedex, FranceTaking people
  • Institut De Cancerologie De L OuestSt Herblain, FranceTaking people
  • Institut public de cancérologie Strauss EuropeStrasbourg, FranceTaking people
  • Les Hopitaux Universitaires De StrasbourgStrasbourg Cedex 2, FranceTaking people
  • Hospital FochSuresnes, FranceTaking people
  • Centre Hospitalier Universitaire De ToulouseToulouse Cedex 9, FranceTaking people
  • Institut De Cancerologie De LorraineVandouvre Les Nancy, FranceTaking people
  • Institut Gustave RoussyVillejuif, FranceTaking people

About the trial

What the trial wants to find out

To assess the activity in terms of progression-free survival (according to RECIST v1.1 per investigator) of dostarlimab compared to standard of care (SOC) as first-line therapy for dMMR/MSI non resectable metastatic or locally advanced non-colorectal and non-endometrial cancers.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Pan-MSI-ACSE: Dostarlimab as first-line treatment for patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer: a randomized phase 2 trial (Cohort Pan-MSI-ACSE) with crossover in the standard arm at progression
Plain-language title
Tests dostarlimab as first treatment for certain mismatch-repair-deficient cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
27 August 2026